Effects of the Japanese Kampo Medicines Rikkunshito, Shakuyakukanzoto and Goreisan on Lenvatinib Plasma Concentrations in Japanese Patients with Thyroid Cancer
Although these Kampo medicines are reported to inhibit drug-metabolizing enzymes and drug transporters, the risk of drug interactions for patients receiving lenvatinib therapy is low. Patients should feel confident that they can receive Kampo medicines as supportive care for lenvatinib therapy without a risk of drug interactions that could affect treatment efficacy.
Authors
- Kiminori Sugino (ORCID: https://orcid.org/0000-0002-9692-9871)
- Koichi Ito (ORCID: https://orcid.org/0000-0002-2042-405X)
- Kazuma Fujita (ORCID: https://orcid.org/0000-0002-8914-9164)
- Akifumi Suzuki (ORCID: https://orcid.org/0000-0002-8555-9238)
- Chie Masaki (ORCID: https://orcid.org/0000-0002-5959-6182)
- Masatomo Miura (ORCID: https://orcid.org/0000-0001-7120-2425)
- Mitsuji Nagahama
Institutions
- Akita University (JP)
- Ito Hospital (JP)
- Akita University Hospital (JP)
- Shibuya (Japan) (JP)
Publication Details
- Journal
- Drugs - Real World Outcomes
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1007/s40801-024-00467-6
- Citations
- 1
- Primary Topic
- PI3K/AKT/mTOR signaling in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.23
Funders
- Tsumura and Company